Attorney Docket No.: I-2002.010 US Customer No.: 31846

## II. Claim Amendments

1. (Currently Amended) An ilmmunogenic composition comprising a fusion protein and a saponin adjuvant, characterized in that the fusion protein comprises a heterologous hydrophobic peptide which is fused to the N-terminus and/or to the C-terminus of a core polypeptide, the core polypeptide comprising at least one protective epitope, the saponin adjuvant being in a free form.

- 2. (Currently Amended) The ilmmunogenic composition according to Celaim 1, characterized in that the core polypeptide is a component of a protein of an organism of the phylum Apicomplexa.
- 3. (Currently Amended) The iImmunogenic composition according to Celaim 2, characterized in that the core polypeptide is a component of a protein of an organism of the Piroplasmida or of the class Coccidia.
- 4. (Currently Amended) The ilmmunogenic composition according to Celaim 3, characterized in that the core polypeptide is a component of a protein of an organism of the genera Eimeria or Babesia.
- 5. (Currently Amended) The iImmunogenic composition according to Claim 1 any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from an N-terminal hydrophobic sequence.
- 6. (Currently Amended) The ilmmunogenic composition according to Claim 1 any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from an internal hydrophobic sequence.

Attorney Docket No.: 1-2002.010 US

Customer No.: 31846

7. (Currently Amended) The ilmmunogenic composition according to Claim 1 any one of claims 1 to 4, characterized in that the heterologous hydrophobic peptide is from a C-terminal hydrophobic sequence.

- 8. (Currently Amended) The ilmmunogenic composition according to Celaim 7, characterized in that the C-terminal hydrophobic sequence is from decay accelerating factor (DAF).
- 9. (Currently Amended) The ilmmunogenic composition according to Claim 1 any one of claims 1 to 8, characterized in that the saponin adjuvant is Quillaja saponin.
- 10. (Currently Amended) <u>A vVaccine characterized in that it comprises an immunogenic composition according to Claim 1 any one of claims 1 to 9 and a pharmaceutically acceptable carrier.</u>
- 11. (Currently Amended) The vV accine according to Celaim 10, characterized in that it comprises at least one additional immunoactive component.
- 12. (Currently Amended) The vV accine according Claim 10 to either one of claims

  10 or 11, characterized in that it is in a freeze-dried form.
- 13. (Currently Amended) The mMethod for the preparation of a vaccine according to claim 10, characterized in that the method comprises admixing an immunogenic composition according to any one of claims 1 to 9 Claim 1 and a pharmaceutically acceptable carrier.
- 14. (Cancelled, without prejudice or disclaimer)